News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure focuses on the most commercially promising projects and closes the RNA program
30 January 2026
Molecure at the threshold of a breakthrough in the treatment of inflammatory and fibrotic diseases. The focus on the most breakthrough therapy and the OATD-01 and OATD-02 clinical trials results in a reduction of programs in the discovery phase from five to three
15 October 2024
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors
15 October 2024
Invitation to investor meeting 16th October 2024, 10:00 am (CET)
14 October 2024
Molecure has released its financial report for the first half of 2024. The company continues to develop innovative therapies in the fight against oncological and inflammatory-fibrotic diseases
27 September 2024
Events & Presentations
EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018
17 September 2018
54th International Conference on Medicinal Chemistry, Strasbourg, France – July 4-6, 2018.
17 July 2018
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017
1 October 2017